Pharvaris (PHVS) Equity Ratio (2020 - 2026)

Pharvaris posted quarterly Equity Ratio of 0.91 for Q1 2026, up 1.09% on a QoQ basis from 0.9 in Q4 2025.

Pharvaris (PHVS) has 7 years of Equity Ratio data on file, last reported at 0.91 in Q1 2026.

  • For the quarter ending Q1 2026, Equity Ratio changed N/A year-over-year to 0.91; the trailing twelve-month figure through Mar 2026 stood at 0.91 (changed N/A YoY), and the FY2025 full-year result was 0.9, down 2.08% from the prior year.
  • Equity Ratio for Q1 2026 stood at 0.91, up from 0.9 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.96 in Q4 2023 and bottomed at 0.89 in Q4 2022.
  • The 5-year median for Equity Ratio is 0.91 (2026), against an average of 0.92.
  • The widest annual swing landed in 2022, when Equity Ratio fell 7.92%; it then advanced 8.25% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 0.89 in 2022, then rose by 8.25% to 0.96 in 2023, then slipped by 4.6% to 0.92 in 2024, then declined by 2.08% to 0.9 in 2025, then gained by 1.09% to 0.91 in 2026.
  • The last three Equity Ratio figures came in at 0.91 (Q1 2026), 0.9 (Q4 2025), and 0.92 (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Ratio (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 0.04
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 0.42
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 0.73
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 0.77
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 0.21
10 Pharvaris 267.74 Mn -73.74 Mn - 0.91

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.91
Dec 31, 2025 0.90
Dec 31, 2024 0.92
Dec 31, 2023 0.96
Dec 31, 2022 0.89
Dec 31, 2021 0.97
Dec 31, 2020 0.95